vs
Side-by-side financial comparison of BioLineRx Ltd. (BLRX) and CaliberCos Inc. (CWD). Click either name above to swap in a different company.
BioLineRx Ltd. is the larger business by last-quarter revenue ($5.4M vs $4.1M, roughly 1.3× CaliberCos Inc.). BioLineRx Ltd. runs the higher net margin — 9.0% vs -188.3%, a 197.3% gap on every dollar of revenue.
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
CaliberCos Inc. is a U.S.-headquartered alternative asset management firm focused primarily on real estate investments. It offers a diverse suite of investment vehicles covering commercial, residential, and industrial real estate assets, serving institutional investors, high-net-worth individuals, and retail clients across North America. It also delivers asset management, property operation, and value-add real estate development services to support consistent long-term returns for investors.
BLRX vs CWD — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.4M | $4.1M |
| Net Profit | $484.0K | $-7.7M |
| Gross Margin | 83.4% | — |
| Operating Margin | -107.0% | -196.6% |
| Net Margin | 9.0% | -188.3% |
| Revenue YoY | — | -52.5% |
| Net Profit YoY | 102.6% | 32.2% |
| EPS (diluted) | $0.00 | $1.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $4.1M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $5.1M | ||
| Q1 25 | — | $7.3M | ||
| Q4 24 | — | $8.7M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | $5.4M | $8.2M | ||
| Q1 24 | — | $23.0M |
| Q4 25 | — | $-7.7M | ||
| Q3 25 | — | $-4.4M | ||
| Q2 25 | — | $-5.3M | ||
| Q1 25 | — | $-4.4M | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | — | $146.0K | ||
| Q2 24 | $484.0K | $-4.7M | ||
| Q1 24 | — | $-3.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 83.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -196.6% | ||
| Q3 25 | — | -129.6% | ||
| Q2 25 | — | -112.4% | ||
| Q1 25 | — | -62.7% | ||
| Q4 24 | — | -236.8% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | -107.0% | -65.0% | ||
| Q1 24 | — | -22.9% |
| Q4 25 | — | -188.3% | ||
| Q3 25 | — | -120.2% | ||
| Q2 25 | — | -104.5% | ||
| Q1 25 | — | -60.7% | ||
| Q4 24 | — | -247.6% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | 9.0% | -57.8% | ||
| Q1 24 | — | -16.6% |
| Q4 25 | — | $1.95 | ||
| Q3 25 | — | $-1.65 | ||
| Q2 25 | — | $-4.15 | ||
| Q1 25 | — | $-3.85 | ||
| Q4 24 | — | $-10.15 | ||
| Q3 24 | — | $0.12 | ||
| Q2 24 | $0.00 | $-4.34 | ||
| Q1 24 | — | $-3.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.6M | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.9M | $1.3M |
| Total Assets | $64.6M | $135.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $10.9M | ||
| Q2 25 | — | $683.0K | ||
| Q1 25 | — | $1.6M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | $9.6M | $1.8M | ||
| Q1 24 | — | $2.1M |
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | — | $-19.9M | ||
| Q1 25 | — | $-15.8M | ||
| Q4 24 | — | $-12.6M | ||
| Q3 24 | — | $-3.8M | ||
| Q2 24 | $13.9M | $-4.7M | ||
| Q1 24 | — | $-745.0K |
| Q4 25 | — | $135.4M | ||
| Q3 25 | — | $82.6M | ||
| Q2 25 | — | $59.3M | ||
| Q1 25 | — | $103.6M | ||
| Q4 24 | — | $105.5M | ||
| Q3 24 | — | $158.6M | ||
| Q2 24 | $64.6M | $195.2M | ||
| Q1 24 | — | $201.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $-12.1M |
| Free Cash FlowOCF − Capex | $-25.5M | — |
| FCF MarginFCF / Revenue | -472.8% | — |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | -52.56× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-12.1M | ||
| Q3 25 | — | $-4.6M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-1.7M | ||
| Q4 24 | — | $555.0K | ||
| Q3 24 | — | $-74.0K | ||
| Q2 24 | $-25.4M | $1.4M | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-25.5M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -472.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.51× | ||
| Q2 24 | -52.56× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
